Table 3.
Methylation rates of the P16, RASSAF1A, RPRM, and RUNX3 in diagnosis of gastric cancer using serum or plasma samples
| Gene | Source | Gastric cancer | Control | Country | Method | Reference |
|---|---|---|---|---|---|---|
| P16 | ||||||
| Serum | 51.9% | 0.0% | Hong Kong | MSP | 25 | |
| Serum | 26.9% | 0.0% | Iran | MSP | 24 | |
| Serum | 79.7% | 2.5% | China | MSP | 23 | |
| Plasma | 41.7% | 15.9% | Iran | MSP | This Study | |
| RASSF1A | ||||||
| Serum | 34.0% | 0.0% | China | MSP | 27 | |
| Serum | 68.5% | 0.0% | Greece | MSP | 19 | |
| Plasma | 83.2% | 5.5% | Thailand | MSP | 26 | |
| Plasma | 33.3% | 0.0% | Iran | MSP | This Study | |
| RPRM | ||||||
| Plasma | 95.3% | 9.7% | Chile | MSP | 28 | |
| Plasma | 62.0%% | 0.0% | China | MSP | 21 | |
| Serum | 94.3% | 7.1% | China | MS-MCA | 22 | |
| Plasma | 86.3% | 7.9% | China | BS | 29 | |
| Plasma | 66.7% | 6.8% | Iran | MSP | This Study | |
| RUNX3 | ||||||
| Serum | 29.0% | 0.0% | Japan | qMSP | 31 | |
| Serum | 70.8% | 0.0% | China | qMSP | 30 | |
| Plasma | 42.7% | 0.0% | China | MSP | 20 | |
| Plasma | 58.3% | 4.5% | Iran | MSP | This Study | |
MS-MCA: Methylation sensitive melt curve analysis; MSP: Methylation specific PCR; q-MSP: quantitative MSP; BS: Bisufite sequencing.